Md. Asad Ullah

Mr. Md. Asad Ullah

Jahangirnagar University
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Immunobiology
Verified
Journal Article
Closed access
BSBishajit Sarkar
Bishajit Sarkar
MUMd. Asad Ullah
Md. Asad Ullah
FJFatema Tuz Johora
Fatema Tuz Johora
MTMasuma Afrin Taniya
Masuma Afrin Taniya
Yusha ArafYusha Araf
Yusha Araf

1 May 2020 in Immunobiology
Verified
Journal Article
Closed access
MUMd. Asad Ullah
Md. Asad Ullah
BSBishajit Sarkar
Bishajit Sarkar
SISyed Sajidul Islam
Syed Sajidul Islam

15 March 2021 in Expert Review of Vaccines
Verified
Journal Article
Closed access
BSBishajit Sarkar
Bishajit Sarkar
MUMd. Asad Ullah
Md. Asad Ullah
Yusha ArafYusha Araf
Yusha Araf
NINafisa Nawal Islam
Nafisa Nawal Islam
UZUmme Salma Zohora
Umme Salma Zohora
Objectives: The group of human coronaviruses (HCoVs) consists of some highly pathogenic viruses that have caused several outbreaks in the past. The newly emerged strain of HCoV, the SARS-CoV-2 is responsible for the recent global pandemic that has already caused the death of hundreds of thousands of people due to the lack of effective therapeutic options. Methods: In this study, immunoinformatics methods were used to design epitope-based polyvalent vaccines which are expected to be effective against four different pathogenic strains of HCoV i.e., HCoV-OC43, HCoV-SARS, HCoV-MERS, and SARS-CoV-2. Results: The constructed vaccines contained highly antigenic, non-allergenic, non-toxic, conserved, and non-homologous T-cell and B-cell epitopes from all the four viral strains. Therefore, they should be able to provide strong protection against all these strains. Protein-protein docking was performed to predict the best vaccine construct. Later, the MD simulation and immune simulation of the best vaccine construct also predicted satisfactory results. Finally, in silico cloning was performed to develop a higher expression strategy of the vaccine. Conclusion: If satisfactory results are achieved in numerous in vivo and in vitro studies, then the vaccines designed in this study might be effective as preventative measures against the selected HCoV strains.

20 September 2021 in Biomarkers in Medicine
Verified
Journal Article
Open access
TTTahani Tabassum
Tahani Tabassum
ARAhsab Rahman
Ahsab Rahman
Yusha ArafYusha Araf
Yusha Araf
MUMd. Asad Ullah
Md. Asad Ullah
MHMohammad Jakir Hosen
Mohammad Jakir Hosen
COVID-19 has become a global health concern, due to the high transmissible nature of its causal agent and lack of proper treatment. Early diagnosis and nonspecific medical supports of the patients ...

30 March 2020 in Journal of Receptors and Signal Transduction
Verified
Journal Article
Closed access
MUMd. Asad Ullah
Md. Asad Ullah
FJFatema Tuz Johora
Fatema Tuz Johora
BSBishajit Sarkar
Bishajit Sarkar
Yusha ArafYusha Araf
Yusha Araf
MD. Hasanur RahmanMD. Hasanur Rahman
MD. Hasanur Rahman
Toll-like receptor 4 (TLR4) pathway is one of the major pathways that mediate the inflammation in human body. There are different anti-inflammatory drugs available in the market which specifically act on different signaling proteins of TLR4 pathway but they do have few side effects and other limitations for intended use in human body. In this study, Curcumin and its different analogs have been analyzed as the inhibitors of signaling proteins, i.e. Cycloxygenase-2 (COX-2), inhibitor of kappaβ kinase (IKK) and TANK binding kinase-1 (TBK-1) of TLR4 pathway using different computational tools. Initially, three compounds were selected for respective target based on free binding energy among which different compounds were reported to have better binding affinity than commercially available drug (control). Upon continuous computational exploration with induced fit docking (IFD), 6-Gingerol, Yakuchinone A and Yakuchinone B were identified as the best inhibitors of COX-2, IKK, and TBK-1 respectively. Then their drug-like potentialities were analyzed in different experiments where they were also predicted to perform well. Hopefully, this study will uphold the efforts of researchers to identify anti-inflammatory drugs from natural sources.

7 August 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
BSBishajit Sarkar
Bishajit Sarkar
MUMd. Asad Ullah
Md. Asad Ullah
Yusha ArafYusha Araf
Yusha Araf
SDSowmen Das
Sowmen Das
MD. Hasanur RahmanMD. Hasanur Rahman
MD. Hasanur Rahman
AMAbu Tayab Moin
Abu Tayab Moin
Herpes Simplex Virus (HSV) is a highly infectious virus that is responsible for various types of orofacial and genital infections. Two types of HSV exist i.e. HSV-1 and HSV-2, that are infecting millions of people around the world. However, no satisfactory treatment or counter-measure has yet been discovered to fight against the HSV infections. In this study, three possible polyvalent subunit vaccines against multiple strains of HSV-1 and HSV-2, targeting the envelope glycoproteins- E, B, and D, were designed using the tools of reverse vaccinology and immunoinformatics. The highly antigenic, non-allergenic, non-toxic, non-homolog (to the human proteome), and 100% conserved epitopes across the selected strains and species (eight epitopes from each of the CTL, HTL, and BCL epitope groups), were selected for vaccine construction. These designed vaccines are expected to be effective against the selected viral types simultaneously (as a polyvalent vaccine), without producing any unwanted adverse reaction within the body. Finally, from the three vaccine constructs, one best vaccine was determined by molecular docking analysis and thereafter, the MD simulation and immune simulation studies of the best vaccine construct also yielded satisfactory results, pointing towards quite good stability of the complex. Finally, in silico cloning was performed for analyzing the effective mass production strategy of the best vaccine construct. However, wet lab-based study should be conducted on the suggested vaccines for validating their potentiality, safety, and efficacy. Communicated by Ramaswamy H. Sarma